Jakafi 15 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FPRP0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,000
Award facts
- Contract value 100% obligated
- $23,999.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $23,999.62 by the Defense Logistics Agency (DLA) on September 24, 2025, for the supply of Jakafi 15 mg tablets (60-count). The award represents a delivery order issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with DLA under the SPE2DB program, a $499.9 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting medical supply needs of military health facilities. No set-aside designation was utilized for this particular delivery order, allowing DMS Pharmaceutical Group to compete on its merits as a small business contractor. The contract requires ultimate completion by September 25, 2025, with performance at the vendor's location in Park Ridge, Illinois.
Jakafi (ruxolitinib) is a prescription medication used to treat myelofibrosis and other myeloproliferative neoplasms, representing the type of specialty pharmaceutical product DMS Pharmaceutical Group routinely supplies to Department of Defense healthcare sites. The company's established role as a critical supplier in the federal pharmaceutical supply chain, combined with its long-standing relationship with DLA and comprehensive product portfolio spanning prescription drugs, biologics, and medical consumables, positions it to fulfill the government's healthcare supply requirements across military medical facilities nationwide.
Quick answers
Who was awarded contract SPE2DB25FPRP0?
SPE2DB25FPRP0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 24, 2025.
How much is contract SPE2DB25FPRP0 worth?
The government has obligated $24,000 on SPE2DB25FPRP0.
Is contract SPE2DB25FPRP0 an order under another contract?
Yes. SPE2DB25FPRP0 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPRP0 competed?
The extent of competition for SPE2DB25FPRP0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award